Lara Dunn
YOU?
Author Swipe
View article: Optimal post-treatment surveillance strategy for human papillomavirus-positive oropharyngeal cancer
Optimal post-treatment surveillance strategy for human papillomavirus-positive oropharyngeal cancer Open
The objective of the current study was to determine the optimal individualized surveillance strategies for human papillomavirus (HPV)-positive oropharyngeal cancer. A consecutive cohort of 1,146 HPV-positive oropharyngeal cancer patients t…
View article: Updated Estimates of Patients With Oropharyngeal Cancer in the US
Updated Estimates of Patients With Oropharyngeal Cancer in the US Open
Importance Updated estimates of oropharyngeal cancer (OPC) in the US are needed. Objective To calculate the most recent epidemiologic estimates of OPC in the US and provide projections for future trends up to 2040. Design, Setting, and Par…
View article: Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC Open
Objective Taxane, platinum, and cetuximab (TPC) is effective as neoadjuvant therapy for advanced head and neck squamous cell carcinoma (HNSCC) and induces pathologic responses that influences clinical outcomes. Study Design Retrospective c…
View article: Coupling Measurements of Biogenic Volatile Organic Compounds and Ozone Reactivity in the Field
Coupling Measurements of Biogenic Volatile Organic Compounds and Ozone Reactivity in the Field Open
The concentration and fate of ozone in the troposphere is dependent on the ratio of volatile organic compounds (VOCs) and NOx gases emitted from both anthropogenic and biogenic sources. The biosphere emits over 1,000 Tg of VOCs annually, o…
View article: Supplementary Data1 from Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma
Supplementary Data1 from Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma Open
Supplementary Data
View article: Data from Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma
Data from Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma Open
Purpose:There is a significant need for effective therapies to treat recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC). This study evaluated the multitargeted VEGFR tyrosine kinase inhibitor (TKI) regorafenib in patients with R/M A…
View article: Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma Open
Purpose: There is a significant need for effective therapies to treat recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC). This study evaluated the multitargeted VEGFR tyrosine kinase inhibitor (TKI) regorafenib in patients with R/M …
View article: Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma Open
PURPOSE Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that m…
View article: Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma
Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma Open
PURPOSE Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)–related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could …
View article: Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors Open
Cemiplimab demonstrated clinically meaningful antitumour activity, including durable responses, and an acceptable safety profile in patients with mBCC who had disease progression on or intolerance to HHI therapy.
View article: 681 innovaTV 207 Parts E and F: a phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress)
681 innovaTV 207 Parts E and F: a phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress) Open
Background Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide. Recently, the introduction of immunotherapy has improved outcomes in the frontline treatment of recurrent/metastatic (r/m) HNSCC, though …
View article: 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients Open
Background Immuno-STATs are modular T cell engagers engineered to selectively activate tumor-antigen specific CD8+ T cells via targeted delivery of cytokines. CUE-101, the first Immuno-STAT in clinical trials, is composed of a human leukoc…
View article: Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer Open
About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration of anti–programmed cell death protein 1 (PD-1) immunotherapy results …
View article: LookUpTrials: Assessment of an artificial intelligence-powered mobile application to engage oncology providers in clinical trials.
LookUpTrials: Assessment of an artificial intelligence-powered mobile application to engage oncology providers in clinical trials. Open
111 Background: Clinical trials are integral to cancer care but face frequent accrual challenges as they grow numerous and complex. Artificial intelligence (AI) technologies can cognitively aid oncology providers, but few have rigorously b…
View article: Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Purpose:Somatic mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110α catalytic subunit of PI3K, are found in multiple human cancers. While recurrent mutations in PIK3CA helic…
View article: Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Supplementary Figures
View article: Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Supplementary Methods
View article: Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Purpose:Somatic mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110α catalytic subunit of PI3K, are found in multiple human cancers. While recurrent mutations in PIK3CA helic…
View article: Supplementary Tables from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Supplementary Tables from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Supplementary Tables
View article: Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Supplementary Methods
View article: Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Supplementary Figures
View article: Supplementary Tables from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Supplementary Tables from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers Open
Supplementary Tables